Albuminuria‐lowering effect of adding semaglutide on top of empagliflozin in individuals with type 2 diabetes: A randomized and placebo‐controlled study
Authors' conclusion
Semaglutide added to empagliflozin did not change UACR, measured GFR, 24-hour systolic blood pressure, body weight or plasma renin levels in individuals with T2D and albuminuria. Semaglutide improved glycaemic control and plasma aldosterone levels compared to placebo.
Study context
- Population
- Individuals with T2D and albuminuria on renin-angiotensin system inhibition
- Participants
- 60 individuals
- Comparison
- Semaglutide vs placebo added to empagliflozin
- Primary endpoint
- Change in UACR
- Follow-up
- Randomization to end-of-treatment (26 weeks)
Methodological detailsplacebo-controlled, double-blind, parallel, 26-week open-label empagliflozin run-in
- Placebo-controlled
- Double-blind
- Parallel
- 26-week open-label empagliflozin run-in
Primary result
As reported in the abstract
randomization to end-of-treatment
- Addition of semaglutide to empagliflozin provided no additional change in urinary albumin-creatinine ratio (UACR)
Secondary outcomes
| Outcome | Difference (mmol/mol) (CI) | P value | |
|---|---|---|---|
| HbA1c | −8 (−13 to −3) | P = 0.003 | |
| −20−10010Difference, mmol/mol (linear scale) |
| Outcome | Difference (pmol/L) (CI) | P value | |
|---|---|---|---|
| Plasma aldosterone | −30 (−50 to −3) | P = 0.035 | |
| −60−40−20020Difference, pmol/L (linear scale) |
Measured glomerular filtration rate (GFR), 24-hour BP, body weight, plasma renin activity
- Not changed with semaglutide
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Albuminuria‐lowering effect of adding semaglutide on top of empagliflozin in individuals with type 2 diabetes: A randomized and placebo‐controlled study. Diabetes Obes Metab. Published 18 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →